EUVIMEDEUVIMED entdecken
Crossref

TSPAN8-mediated Epithelial-mesenchymal Transition Drives Acquired Radioresistance in Cervical Cancer

Jing-Nan Wang, Ling-Li Liao, Fan Yang, Ru Wang, Lei Zhang, Ao-Xue Li, Peng-Jie Yu, Ruo-Tong Wu, Nuo Chen, Yu-Qiao Xu, Yong-Chun Zhou

Radiation Research · 2026

DOI: 10.1667/rade-25-00233.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Research, 2026. Verfasst von Jing-Nan Wang und 10 weiteren Autor:innen. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Epithelial-Mesenchymal Transition, Radiation Tolerance, Tetraspanins. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired radioresistance remains a major obstacle to effective radiotherapy for cervical cancer, often driven by epithelial-mesenchymal transition (EMT). This study reveals TSPAN8 as a novel regulator of EMT-mediated radioresistance, offering new insights for overcoming treatment failure. Radioresistant subclones of HeLa-R25 and SiHa-R25 cells were established by repeated 2 Gy fractions. Radioresistance, apoptosis, EMT, and stemness were assessed by clonogenic survival, flow cytometry, immunoblotting, and immunofluorescence. Differentially expressed genes were identified by microarray, validated by protein-protein interaction analysis and co-immunoprecipitation, and functionally examined via TSPAN8 overexpression/knockdown, xenograft models, and immunohistochemistry of primary, metastatic, and recurrent post-radiotherapy specimens. Prognostic relevance was analyzed in the TCGA-CESC cohort. Fractionated irradiation induced EMT and radioresistance, with significantly higher clonogenic survival in R25 cells (P < 0.05), characterized by E-cadherin loss, N-cadherin/Vimentin upregulation, and increased CD44/ Oct4. TSPAN8 was the most upregulated gene and directly interacted with E-cadherin. Overexpression enhanced EMT, invasion, and resistance to apoptosis, while knockdown reversed these effects and restored radiosensitivity in vivo. TSPAN8 knockdown in radioresistant xenografts significantly suppressed tumor growth (P < 0.05), and combined knockdown with irradiation further reduced tumor volume (P < 0.05). In patient samples, post-radiotherapy recurrences and metastases exhibited high TSPAN8 and vimentin with reduced E-cadherin. TCGA data confirmed that elevated TSPAN8 was associated with worse outcomes, including shorter disease-specific survival (HR = 2.02, 95% CI 1.01–3.71, P = 0.02) and progression-free survival (HR = 3.09, 95% CI 1.80–5.30, P < 0.001). These data suggest that TSPAN8 drives EMT-mediated radioresistance in cervical cancer, is associated with recurrence and poor survival, and represents a potential biomarker and therapeutic target. Targeting TSPAN8 may enhance radiosensitivity and improve personalized radiotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsEpithelial-Mesenchymal TransitionRadiation ToleranceTetraspaninsFemaleHumansAnimalsMiceApoptosisGene Expression Regulation, NeoplasticCell Line, TumorHeLa Cells

Substanzen

TetraspaninsTSPAN8 protein, human

Zitieren

APA

Wang, J. N., Liao, L. L., Yang, F., Wang, R., Zhang, L., Li, A. X., Yu, P. J., Wu, R. T., Chen, N., Xu, Y. Q., & Zhou, Y. C. (2026). TSPAN8-mediated Epithelial-mesenchymal Transition Drives Acquired Radioresistance in Cervical Cancer. Radiation Research. https://doi.org/10.1667/rade-25-00233.1

Vancouver

Wang JN, Liao LL, Yang F, Wang R, Zhang L, Li AX, et al. TSPAN8-mediated Epithelial-mesenchymal Transition Drives Acquired Radioresistance in Cervical Cancer. Radiation Research. 2026. doi:10.1667/rade-25-00233.1

BibTeX
@article{Wang2026,
  author = {Wang, Jing-Nan and Liao, Ling-Li and Yang, Fan and Wang, Ru and Zhang, Lei and Li, Ao-Xue and Yu, Peng-Jie and Wu, Ruo-Tong and Chen, Nuo and Xu, Yu-Qiao and Zhou, Yong-Chun},
  title = {TSPAN8-mediated Epithelial-mesenchymal Transition Drives Acquired Radioresistance in Cervical Cancer},
  journal = {Radiation Research},
  year = {2026},
  doi = {10.1667/rade-25-00233.1}
}
Kostenlos starten →